Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized conversion study of belatacept in pediatric stable renal transplant recipients
2011-005257-31Phase 2
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of belatacept in kidney allograft rejection and Kidney allograft status (RTx) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary pharmacokinetics endpoint.
02
Drugs
belatacept
03
Conditions
kidney allograft rejectionKidney allograft status (RTx)
Beyond the preview
Go deeper on 2011-005257-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005257-31.